Special Issue "Biomarkers in Hepatocellular Carcinoma"
Deadline for manuscript submissions: closed (30 June 2021).
Interests: NAFLD; NASH; HCV; ALD; liver cirrhosis; HCC; portal hypertension; elastography
Hepatocellular Carcinoma (HCC) is the sixth most common cancer and the third cancer-related cause of death, with more than 800,000-related deaths each year. In such a complicated scenario, tools for early diagnosis and prognosis prediction are fundamental for patient stratification.
HCC early diagnosis is currently achieved by ultrasound screening in cirrhotic patients, accompanied by evaluation in alpha-fetoprotein (AFP) fluctuation over time. However, this screening strategy is far from perfect, especially considering that even patients with liver disease and without advanced fibrosis can develop HCC.
With advances in the understanding of tumor biology, along with the development of cellular and molecular techniques, the use of biomarkers related to early detection, invasiveness, metastasis, and recurrence have attracted a great deal of investigative interest resulting in the identification and utilization of several novel markers in this disease. This Special Issue will address the current advances in biomarkers in HCC.
Prof. Dr. Lory Saveria Croce'
Dr. Mauro Giuffrè
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Liver Cirrhosis
- Hepatocellular Carcinoma
- Diagnostic Biomarkers
- Prognostic Biomarkers
- Early Diagnosis